Initial Presentation Sites as Predictors of Herpes Zoster Complications: A Nationwide Cohort Study

Wen-Yi Wang¹, Sing-Huh Liu¹, Meng-Yin Lin²,³, Che-Chen Lin⁴,⁵, I-Jong Wang¹,⁶ *

¹ Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan, ² Department of Ophthalmology, Shuang Ho Hospital, Taipei Medical School of Medicine, Taipei Medical University, Taipei County, Taiwan, ³ Institute of Clinical Medicine, School of Medicine, National Taiwan University, Taipei, Taiwan, ⁴ Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan, ⁵ School of Medicine, China Medical University, Taichung, Taiwan, ⁶ Institute of Clinical Medicine, School of Medicine, China Medical University, Taichung, Taiwan

* ijong@ms8.hinet.net

Abstract

Herpes zoster (HZ) is associated with complications such as postherpetic neuralgia (PHN) and HZ ophthalmicus (HZO). However, few studies have focused on identifying patients having a high risk of PHN and HZO according to the initial presentation sites. The current study investigated these factors in a nationwide population-based cohort derived from Taiwan’s Longitudinal Health Insurance Database. The results indicate that the initial presentation sites can predict the complication site of HZ. In this study, elderly patients were found to be more susceptible to HZ and were the first to present with neurological signs (HZN). Furthermore, compared with patients with HZO and other signs (HZT), those with HZN had a higher comorbidity risk. Patients with HZN showed a significantly higher visceral complication risk than did those with HZO (adjusted hazard ratio [HR] = 1.47, 95% confidence interval [CI] = 1.27–1.71). In addition, patients with HZT showed lower risks of ocular and neurological complications than did those with HZN after stratification by age and sex (adjusted HR = 0.46, 95% CI = 0.31–0.68 and HR = 0.73, 95% CI = 0.59–0.91, respectively).

Introduction

Reactivation of the latent varicella—zoster virus (VZV) in the cranial nerve or dorsal root ganglia leads to herpes zoster (HZ), also known as shingles [1]. Typically, HZ causes unilateral cutaneous pain and blistering rashes that are limited to one dermatome [1]. The estimated incidence rate of HZ is 30%. However, approximately 50% of unvaccinated people aged ≤85 years develop HZ [2–4]. The global incidence rate of HZ is 3–5/1000 person-years, sharply increasing after the age of 50 years [3]. The global incidence rate is estimated to be approximately 6–8 and 10–12/1000 person-years in people aged 60 and ≥80 years, respectively [3, 5].
HZ is common and increasingly prevalent; it causes debilitating pain, neuropathy, and inflammatory complications, leading to high health care expenditure and productivity loss [2, 4, 6–8]. Moreover, accumulating evidence has indicated that HZ may increase the risk of other severe conditions, particularly stroke [9, 10]. HZ is associated with complications, mainly post-herpetic neuralgia (PHN) and HZ ophthalmicus (HZO) [3, 11]. Approximately 10%–18% of patients with HZ develop PHN, which is characterized by persistent pain after the resolution of the rash [12]. However, >30% of patients with PHN experience pain lasting for >1 year [3]. The prevalence of HZO is 10%–25% among patients with HZ, arising because of reactivation of the latent virus in the trigeminal ganglia involved in the ophthalmic division of the trigeminal nerve [9]. Patients with HZO require medical care for an average of 10 months, and 6% of these patients develop vision loss [13].

HZ occurs in patients with poor cell-mediated immunity [14], which diminishes with age and immune deficiency or suppression [12, 15]. Patients aged >50 years who take immunosuppressive drugs, have HIV/AIDS, or have undergone bone marrow or organ transplants have a high risk of HZ [5, 16, 17]. Other risk factors include cancer, chronic steroid therapy, psychological stress, sex, ethnicity, primary infection during infancy or in utero, and trauma [15, 18–20]. Moreover, HZ complications are intolerable and result in patient disability. Therefore, elucidating the risk factors for extremely painful and vision-threatening complications is imperative for identifying patients having a high risk of HZ and its complications. Many studies have indicated that greater acute pain and rash severities and prodromal pain are predictors of PHN [21–27]. However, few population-based studies have focused on HZO [11]. Moreover, according to our review of relevant literature, no studies have yet identified patients at high risks of PHN and HZO according to the initial presentation sites.

Therefore, this study investigated the association between the initial presentation and complication sites of HZ in a nationwide population-based cohort in Taiwan. Moreover, different complications in the cohorts were evaluated after stratification by age and sex.

**Methods**

**Data source**

The study population was derived from the Longitudinal Health Insurance Database (LHID). The LHID contains the data of one million randomly selected enrollees of the National Health Insurance (NHI) program, a single-payer, mandatory health insurance program covering the 23 million residents of Taiwan, for the period 1996–2000. According to a report published by the Taiwan government, age and sex distributions in the LHID and NHI program do not differ significantly. The LHID comprises the claims data of the NHI program, including the registry of beneficiaries; inpatient and outpatient files, in which the disease history is recorded using International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes; and data on other medical services. The LHID was released for research after encrypting the original identification numbers of the insurance beneficiaries to protect patient privacy. This study was approved by the Ethics Review Board of China Medical University (CMUH104-REC2-115).

**Study population**

This retrospective population-based cohort study elucidated the association between the risk of HZ complications and types of HZ. The study cohort comprised patients who had newly developed HZ (ICD-9-CM 053) between January 1, 2000 and December 31, 2009. Patients who received previous HZ coding within 180 days before the index date were excluded, and those with missing information on sex or age were not enrolled. The patients were classified into the
following cohorts. 1) HZO: patients with an initial ICD-9-CM codes of 053.20, 053.21, 053.22, or 053.29; 2) HZN: patients with initial ICD-9-CM codes of 053.11, 053.0, 053.71, and 053.19; and 3) HZT: patients with ICD-9-CM codes different from those for HZO and HZN. The index date in the HZ cohort was the date of the initial HZ diagnosis. All patients who experienced HZ complications before the index date were excluded from the study. The following HZ complications were studied: cutaneous (ICD-9-CM 680–686, 035, 728, 034, and 041); ocular (ICD-9-CM 379.00, 379.09, 373.00, 376.01, 376.00, 365.60, 364.10, 364.00, 362.89, 363.20, 360.12, 370.00, 371.00, 370.50, 370.35, 370.60, and 371.43 or HZ coding changed to ICD-9-CM 053.2); neurological (ICD-9-CM 320–323, 342, 348, 351, 378, 438.2, 780.3, and V17.1 or HZ coding changed to ICD-9-CM 053.0 and 053.1); primary trigeminal neuralgia (PTN, with PTN drug use); and other visceral (ICD-9-CM 038, 040, 041, 070.5, 070.9, 730–733, 480–487, 466, 490, 422, 425, 510–519, 287, 790.7, 995.91, 995.92, 573, and 577.0 or HZ coding changed to ICD-9-CM 053.8, 053.79, and 053.71) outcomes. Each patient was followed until the occurrence of an HZ complication; withdrawal from the NHI program; or December 31, 2011.

The following comorbidities were considered confounders: coronary artery disease (ICD-9-CM 410–414), hypertension (ICD-9-CM 401–405), hyperlipidemia (ICD-9-CM 272), diabetes mellitus (DM, ICD-9-CM250), stroke (ICD-9-CM 430–438), atrial fibrillation (AF; ICD-9-CM 427.31), renal disease (ICD-9-CM 580–589), heart failure (ICD-9-CM 428), cancer (ICD-9-CM 140–208), chronic hepatitis (ICD-9-CM 571, 572.2, 572.3, 572.8, 573.1–573.3, 573.8, 573.9), and systemic lupus erythematosus (SLE, ICD-9-CM 710).

Statistical analysis

The mean age and corresponding standard deviation were calculated, and the age difference in the HZ cohorts was determined using an analysis of variance test. In addition, the number and percentage for sex and comorbidities were calculated, and the differences in their distribution in the cohorts were assessed using the chi-squared test. The incidence density of each HZ complication in each HZ cohort was calculated as the total number of complication events divided by the sum of the follow-up period (per 1000 person-years). Furthermore, the overall cumulative incidence of HZ complications in each HZ cohort was measured using the Kaplan—Meier method, and the curve differences were determined using the log-rank test. To estimate the risk of HZ complications in the HZ cohorts, the hazard ratios (HRs) and 95% confidence intervals (CIs) were measured using crude and adjusted Cox proportional hazards models. The risk of HZ complications in the HZO, HZN, and HZT cohorts was analyzed after stratification by age and sex. SAS version 9.4 (SAS Institute, Cary, NC, USA) was used for data management and integration and for all statistical analyses. The statistical significance was set at p < 0.05.

Results

Table 1 lists the studied characteristics of the three cohorts. The HZO, HZN, and HZT cohorts comprised 660, 1388, and 22,495 patients, respectively. The mean patient ages in the HZO, HZN, and HZT cohorts were 57.3, 57.6, and 54.9 years, respectively. The sex ratio did not significantly differ among the three cohorts (p = 0.2783). In addition, the proportion of patients with DM, AF, heart failure, chronic hepatitis, and SLE did not significantly differ among the cohorts.

Table 2 lists the risk of HZ complications in all cohorts. Fig 1 shows a significant overall incidence of HZ complications in the HZ cohorts (log-rank test, p < 0.0001). The incidence of cutaneous complications in the HZO, HZN, and HZT cohorts was 7.77, 7.46, and 6.16/1000 person-years, respectively. Compared with the HRs in the HZO cohort, the HRs for cutaneous...
outcomes were 0.90 (95% CI = 0.58–1.40) and 0.84 (95% CI = 0.58–1.21) in the HZN and HZT cohorts, respectively. After adjustment for age, sex, and comorbidities, the HR for PTN was 1.20 (95% CI = 0.83–1.74) in the HZN cohort and 0.93 (95% CI = 0.68–1.29) in the HZT cohort compared with the HZO cohort. The HZT cohort showed a 0.46-fold lower risk of ocular complications relative to that of the HZN cohort (HR = 0.46, 95% CI = 0.31–0.68). The HZT cohort had a 0.73-fold lower risk of neurological complications than did the HZO cohort (HR = 0.73, 95% CI = 0.59–0.91). In addition, the HZN cohort was more significantly associated with an increased risk of other visceral complications than was the HZO cohort (HR = 1.47, 95% CI = 1.27–1.71).

Tables 3–7 shows the risk of HZ complications in the HZ cohorts after stratification by age and sex. Table 3 shows the risk of cutaneous outcomes were 0.90 (95% CI = 0.58–1.40) and 0.84 (95% CI = 0.58–1.21) in the HZN and HZT cohorts, respectively. After adjustment for age, sex, and comorbidities, the HR for PTN was 1.20 (95% CI = 0.83–1.74) in the HZN cohort and 0.93 (95% CI = 0.68–1.29) in the HZT cohort compared with the HZO cohort. The HZT cohort showed a 0.46-fold lower risk of ocular complications relative to that of the HZN cohort (HR = 0.46, 95% CI = 0.31–0.68). The HZT cohort had a 0.73-fold lower risk of neurological complications than did the HZO cohort (HR = 0.73, 95% CI = 0.59–0.91). In addition, the HZN cohort was more significantly associated with an increased risk of other visceral complications than was the HZO cohort (HR = 1.47, 95% CI = 1.27–1.71).

Tables 3–7 shows the risk of HZ complications in the HZ cohorts after stratification by age and sex. Table 3 shows the risk of cutaneous outcomes. The risk of cutaneous

Table 1. Demographic status and comorbidities in the study cohorts.

| Variable       | HZO, N = 660 (%) | HZN, N = 1388 (%) | HZT, N = 22495 (%) | p-value |
|----------------|------------------|-------------------|--------------------|---------|
| Age, years (SD)† | 57.3 (17.5)      | 57.6 (16.5)       | 54.9 (16.7)        | <0.0001 |
| Sex            |                  |                   |                    |         |
| Female         | 341 (51.7)       | 715 (51.5)        | 12013 (53.4)       | 0.2783  |
| Male           | 319 (48.3)       | 673 (48.5)        | 10482 (46.6)       |         |
| Comorbidity    |                  |                   |                    |         |
| CAD            | 188 (28.5)       | 430 (31.0)        | 5403 (24.0)        | <0.0001 |
| Hypertension   | 299 (45.3)       | 645 (46.5)        | 9013 (40.1)        | <0.0001 |
| Hyperlipidemia | 190 (28.8)       | 484 (34.9)        | 6593 (29.3)        | <0.0001 |
| DM             | 107 (16.2)       | 221 (15.9)        | 3257 (14.5)        | 0.1666  |
| Stroke         | 38 (5.8)         | 85 (6.1)          | 966 (4.3)          | 0.0014  |
| AF             | 16 (2.4)         | 33 (2.4)          | 379 (1.7)          | 0.0641  |
| Renal disease  | 104 (15.8)       | 248 (17.9)        | 2821 (12.5)        | <0.0001 |
| Heart failure  | 48 (7.3)         | 112 (8.1)         | 1237 (5.5)         | <0.0001 |
| Cancer         | 32 (4.8)         | 68 (4.9)          | 980 (4.4)          | 0.5383  |
| Chronic hepatitis | 212 (32.1) | 452 (32.6) | 6872 (30.5) | 0.2085  |
| SLE            | 1 (0.2)          | 6 (0.4)           | 89 (0.4)           | 0.5931  |

†ANOVA test.

Abbreviations: CAD: coronary artery disease (ICD-9-CM 410–414); DM: diabetes mellitus (ICD-9-CM 272); AF: atrial fibrillation (ICD-9-CM 427.31); SLE: systemic lupus erythematosus (ICD-9-CM 710), hypertension (ICD-9-CM 401–405), hyperlipidemia (ICD-9-CM 272), stroke (ICD-9-CM 430–438), renal disease (ICD-9-CM 580–589), heart failure (ICD-9-CM 428), cancer (ICD-9-CM 140–208), and chronic hepatitis (ICD-9-CM 571, 572.2, 572.3, 572.8, 573.1–573.3, 573.8, and 573.9)

doi:10.1371/journal.pone.0164019.t001

Table 2. Adjusted hazard ratios (95% confidence interval) for herpes zoster complication risk.

| Type of outcome | HZO | HZN | HZT |
|----------------|-----|-----|-----|
|                | Event | Rate | Adjusted HR (95% CI) | Event | Rate | Adjusted HR (95% CI) | Event | Rate | Adjusted HR (95% CI) |
| Cutaneous      | 30   | 7.77 | ref | 58  | 7.46 | 0.90 (0.58–1.40) | 805  | 6.16 | 0.84 (0.58–1.21) |
| Ocular         | -    | -    | ref | 29  | 3.65 | ref | 205  | 1.53 | 0.46 (0.31–0.68) |
| Neurologic     | 82   | 22.9 | ref | -   | -    | -   | 1885 | 15.1 | 0.73 (0.59–0.91) |
| PTN            | 39   | 10.1 | ref | 98  | 12.6 | 1.20 (0.83–1.74) | 1163 | 8.90 | 0.93 (0.68–1.29) |
| Other visceral | 229  | 79.9 | ref | 651 | 143  | 1.47 (1.27–1.71) | -    | -    | - |

doi:10.1371/journal.pone.0164019.t002
outcomes in the HZN and HZT cohorts was not significantly different compared with that in the HZO cohort after stratification by age and sex. Table 4 lists the ocular risk in the study cohorts stratified by age and sex. Compared with the HRs in the HZN cohort, those for ocular complications were 0.54 (95% CI = 0.30–0.99) for female patients and 0.40 (95% CI = 0.24–0.68) for male patients in the HZT cohort. Except for patients in the ≥65-year age group, those in all other age groups in the HZT cohort exhibited a significantly lower risk of ocular complications than did those in the <45-year (HR = 0.20, 95% CI = 0.09–0.43) and 45–64-year (HR = 0.37, 95% CI = 0.20–0.69) age groups in the HZN cohort. Table 5 presents the risk of neurological complications in the HZO and HZT cohorts stratified by age and sex. The risk of neurological complications was significantly lower in the HZT cohort than in the HZO cohort only for patients aged 45–64 years (HR = 0.55, 95% CI = 0.38–0.80) and male patients (HR = 0.62, 95% CI = 0.46–0.82). Table 6 presents the PTN outcomes for all HZ cohorts. Compared with the risk of PTN in the HZO cohort, that in the HZN and HZT cohorts stratified by age

---

**Table 3. Risk of herpes zoster complications (cutaneous) in types of herpes zoster stratified by age and sex.** Adjusted HR: Adjusted for age, sex, CAD, hypertension, hyperlipidemia, DM, stroke, AF, renal disease, heart failure, cancer, chronic hepatitis, and SLE. Rate: incidence rate per 1000 person-years.

| Variable | HZO | HZN | HZT |
|----------|-----|-----|-----|
|          | Event | Rate | Adjusted HR (95% CI) | Event | Rate | Adjusted HR (95% CI) | Event | Rate | Adjusted HR (95% CI) |
| Age group |       |     |                    |       |     |                    |       |     |                    |
| <45      | 2     | 1.84 | ref                | 7     | 3.76 | 1.84(0.38–8.89)     | 131   | 3.38 | 1.70(0.42–6.87)     |
| 45–64    | 12    | 8.76 | ref                | 18    | 5.26 | 0.58(0.28–1.20)     | 292   | 5.11 | 0.57(0.32–1.02)     |
| ≥65      | 16    | 11.4 | ref                | 33    | 13.2 | 1.06(0.58–1.93)     | 382   | 11.0 | 0.94(0.57–1.56)     |
| Sex      |       |     |                    |       |     |                    |       |     |                    |
| Female   | 12    | 5.79 | Ref                | 28    | 6.86 | 1.07(0.54–2.11)     | 394   | 5.56 | 0.97(0.55–1.72)     |
| Male     | 18    | 10.1 | Ref                | 30    | 8.11 | 0.80(0.45–1.44)     | 411   | 6.88 | 0.76(0.47–1.21)     |

---

Fig 1. Overall cumulative risks of complications in the HZO, HZN, and HZT cohorts.

doi:10.1371/journal.pone.0164019.g001
Table 4. Risk of herpes zoster complications (ocular) in different types of herpes zoster stratified by age and sex. Adjusted HR: Adjusted for age, sex, CAD, hypertension, hyperlipidemia, DM, stroke, AF, renal disease, heart failure, cancer, chronic hepatitis, and SLE. Rate: incidence rate per 1000 person-years.

| Variable | HZO | HZN | HZT |
|----------|-----|-----|-----|
| Event    | Rate| Adjusted HR (95% CI) | Event | Rate| Adjusted HR (95% CI) | Event | Rate| Adjusted HR (95% CI) |
| Age group| -   | -   | -   | 8   | 4.32 | ref | 31   | 0.79 | 0.20(0.09–0.43) |
|          | 45–64| -   | -   | 12  | 3.45 | ref | 73   | 1.25 | 0.37(0.20–0.69) |
| ≧65      | -   | -   | -   | 9   | 3.45 | ref | 101  | 2.79 | 0.86(0.44–1.71) |
| Sex      | Female| -   | -   | 12  | 2.89 | ref | 102  | 1.41 | 0.54(0.30–0.99) |
|          | Male| -   | -   | 17  | 4.49 | ref | 103  | 1.68 | 0.40(0.24–0.68) |

doi:10.1371/journal.pone.0164019.t004

Table 5. Risk of herpes zoster complications (neurological) in different types of herpes zoster stratified by age and sex. Adjusted HR: Adjusted for age, sex, CAD, hypertension, hyperlipidemia, DM, stroke, AF, renal disease, heart failure, cancer, chronic hepatitis, and SLE. Rate: incidence rate per 1000 person-years.

| Variable | HZO | HZN | HZT |
|----------|-----|-----|-----|
| Event    | Rate| Adjusted HR (95% CI) | Event | Rate| Adjusted HR (95% CI) | Event | Rate| Adjusted HR (95% CI) |
| Age group| <45 | 9   | 8.60 | ref | -   | -   | -   | 188  | 4.89 | 0.54(0.28–1.06) |
|          | 45–64| 30  | 23.6 | ref | -   | -   | -   | 722  | 13.2 | 0.55(0.38–0.80) |
|          | ≧65 | 43  | 33.8 | ref | -   | -   | -   | 975  | 30.6 | 0.89(0.66–1.21) |
| Sex      | Female| 32  | 16.3 | ref | -   | -   | -   | 984  | 14.5 | 0.92(0.65–1.31) |
|          | Male| 50  | 30.7 | ref | -   | -   | -   | 901  | 15.7 | 0.62(0.46–0.82) |

doi:10.1371/journal.pone.0164019.t005

Table 6. Risk of herpes zoster complications (primary trigeminal neuralgia) in different types of herpes zoster stratified by age and sex. Adjusted HR: Adjusted for age, sex, CAD, hypertension, hyperlipidemia, DM, stroke, AF, renal disease, heart failure, cancer, chronic hepatitis, and SLE. Rate: incidence rate per 1000 person-years.

| Variable | HZO | HZN | HZT |
|----------|-----|-----|-----|
| Event    | Rate| Adjusted HR (95% CI) | Event | Rate| Adjusted HR (95% CI) | Event | Rate| Adjusted HR (95% CI) |
| Age group| <45 | 5   | 4.63 | ref | 14  | 7.56 | 1.48(0.53–4.12) | 177  | 4.55 | 0.89(0.37–2.18) |
|          | 45–64| 12  | 8.75 | ref | 38  | 11.1 | 1.22(0.64–2.33) | 464  | 8.12 | 0.92(0.52–1.64) |
|          | ≧65 | 22  | 15.7 | ref | 46  | 18.4 | 1.12(0.67–1.86) | 522  | 15.0 | 0.95(0.62–1.46) |
| Sex      | Female| 23  | 11.2 | ref | 59  | 14.6 | 1.23(0.76–1.99) | 663  | 9.39 | 0.85(0.56–1.28) |
|          | Male| 16  | 8.90 | ref | 39  | 10.4 | 1.18(0.66–2.11) | 500  | 8.32 | 1.08(0.66–1.78) |

doi:10.1371/journal.pone.0164019.t006
Discussion

According to our review of relevant literature, this is the first population-based study clarifying the relationship between the initial presentation sites and HZ complications. We observed that the overall cumulative incidence of HZ complications in each HZ cohort was clinically significant (log-rank test, \( p < 0.0001 \)), with the highest and lowest complication rates in the HZN and HZT cohorts, respectively (Fig 1 and Table 2). In this study, the HZN cohort was associated with a higher risk of ocular complications than was the HZT cohort (Table 2). Moreover, the HZO cohort showed a higher risk of neurological complications than did the HZT cohort (Table 2). Few large-scale studies have focused on the relationship between initial presentation sites and HZ complications. We conducted a literature review and found two similar population-based cohort studies in Taiwan that had documented an increased risk of stroke after HZO [10, 28]. One study reported that the adjusted HRs for stroke after HZ and HZO during the 1-year follow-up period were 1.31 and 4.28, respectively. The other study compared 658 patients with HZO and 1974 controls and reported a mean 4.52-fold increased risk of stroke [10, 28]. Because the neurological complications may occur several months after an HZO event, the association is often overlooked. In this study, we indicated the relevance of this association to facilitate early detection. Our findings highlight that the initial presentation site can be an early predictor of neurological and ocular complications of HZ. However, additional studies are warranted to confirm our findings and explore the underlying pathogenesis.

Furthermore, to eliminate possible confounders, the association of initial presentation sites with complications was adjusted by comorbidities. We also analyzed the effects of sex and age by using stratification analyses and observed an increased risk of these complications in older age groups, which is compatible with previous studies [5, 29]. Our results revealed no significant difference between men and women in the type of HZ complication (Tables 3–7). Like previous studies, [1, 11, 30], we could not ascertain the relationship between sex and the incidence of HZ complications. We reason that decreased cell-mediated immunity leads to VZV reactivation [14, 29]. Elderly patients with age-related decreased cell-mediated immunity or immunocompromised patients, including recipients of organ or hematopoietic stem-cell transplants; those receiving immunosuppressive therapy; and those with lymphoma, leukemia, or HIV infection, have an increased risk of HZ [1, 31, 32]. Cancer patients with relatively impaired immunity develop significantly more nonpainful HZ symptoms but an equal number of pain-related HZ complications [33]. Our results regarding the initial presentation sites revealed significant differences in nonpainful complications (ocular, neurological, and other visceral complications) but not in PHN and cutaneous complications. Although the mechanism of this phenomenon remains unknown, some studies have speculated on the basis of

| Variable | HZO | | | HZN | | | HZT | | |
|---|---|---|---|---|---|---|---|---|---|
| **Event Rate** | Adjusted HR (95% CI) | Event Rate | Adjusted HR (95% CI) | Event Rate | Adjusted HR (95% CI) | Event Rate | Adjusted HR (95% CI) | Event Rate | Adjusted HR (95% CI) |
| **Age group** | | | | | | | | | |
| <45 | 43 | 48.7 | Ref | 116 | 91.8 | 1.68 (1.17–2.39) | - | - | - |
| 45–64 | 78 | 78.5 | Ref | 273 | 144 | 1.55 (1.21–2.00) | - | - | - |
| ≥65 | 108 | 109 | Ref | 262 | 186 | 1.34 (1.07–1.68) | - | - | - |
| **Sex** | | | | | | | | | |
| Female | 108 | 67.9 | Ref | 350 | 149 | 1.76 (1.41–2.18) | - | - | - |
| Male | 121 | 94.9 | Ref | 301 | 135 | 1.24 (1.00–1.53) | - | - | - |

doi:10.1371/journal.pone.0164019.t007

Table 7. Risk of herpes zoster complications (other visceral) in different types of herpes zoster stratified by age and sex. Adjusted HR: Adjusted for age, sex, CAD, hypertension, hyperlipidemia, DM, stroke, AF, renal disease, heart failure, cancer, chronic hepatitis, and SLE. Rate: incidence rate per 1000 person-years.
herpes virus that the mechanism involves retrograde axonal transport within the oculomotor nerve to the brain or along the optic nerve to the eyes [34–36]. Additional studies are warranted to elucidate the mechanism through which the locations of HZ reactivation are determined.

The use of the LHID strengthens the validity of this study in the following aspects. First, this study had a large sample size (24,543 patients with HZ) and a long-term follow-up period (10 years), which extensively increased its statistical power. Second, this study is highly representative of the Taiwanese population because the NHI program covers 99% of the 23 million residents and has contracts with 97% of hospitals and clinics in Taiwan [37, 38]. These hospitals and clinics are densely distributed, highly accessible, and charge very low fees. All beneficiaries are eligible for receiving medical services by paying a nominal copayment of US $3–$15 for each visit [39]; therefore, most patients with a painful disease such as HZ are strongly motivated to visit physicians.

Several limitations of this study should be addressed. First, potential miscoding and misdiagnosis may have hampered the present results. Nevertheless, all insurance claims in the NHI program are filed by board-certified physicians, scrutinized by medical reimbursement specialists, and subjected to peer review. In addition, considering the distinctive appearance of HZ, the diagnosis of HZ is relatively simple. Furthermore, we excluded some symptom-based diagnosis codes, such as ICD-9-CM 729.2 for neuralgia, 784.0 for facial pain, and 698.9 for itching. Therefore, the diagnoses and codes for HZ infection should be accurate and reliable. Data from the NHI program have been validated and applied widely in several HZ epidemiological studies [4, 30, 40, 41]. Second, in previous studies, approximately 2.3%–6.2% of patients experienced HZ recurrence during a follow-up period of 8–10 years [42, 43]. A review of 859 patients revealed that 83% of them had one complication, 12% had two complications, and 5% had three or more complications [44]. In this study, we could not determine whether the second HZ event was a recurrence or complication; therefore, complications at the initial presentation sites were excluded to prevent this type of misclassification. Third, although we adjusted for the comorbidities and basic demographic data of the patients in the analysis, other factors reportedly associated with HZ, such as psychological status, previous trauma, and prodromal pain, were not observed in this study [21, 45, 46]. The relationship among these factors was not recorded in the LHID; thus, these factors were not included in our study design.

In summary, our results revealed that the initial presentation sites might be highly associated with subsequent complication sites. Our results are expected to benefit physicians and increase their awareness regarding HZ complications and different presentation sites. This study is the first to investigate epidemiological data on the relationship between the initial presentation sites and complication sites of HZ. Additional studies are required to provide conclusive results regarding the predictors of HZ complications.

Acknowledgments
This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019); China Medical University Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037); NRPB Stroke Clinical Trial Consortium (MOST 104-2325-B-039–005); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

Author Contributions
Conceptualization: IJW SHL.
Data curation: CCL.
Formal analysis: WYW CCL IJW SHL.
Funding acquisition: CCL IJW.
Investigation: WYW IJW.
Methodology: CCL IJW SHL.
Project administration: IJW.
Resources: CCL IJW.
Software: CCL.
Supervision: IJW.
Validation: CCL IJW SHL.
Visualization: WYW SHL MYL CCL IJW.
Writing – original draft: WYW SHL MYL CCL IJW.

References
1. Cohen JL. Clinical practice: Herpes zoster. N Engl J Med. 2013; 369(3):255–63. doi: 10.1056/NEJMcp1302674 PMID: 23863052
2. Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans. Psychiatr Serv. 2008; 59(10):1184–90. doi: 10.1176/appi.ps.59.10.1184 PMID: 18932505
3. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014; 4(6):e004833. doi: 10.1136/bmjopen-2014-004833 PMID: 24916088
4. Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010; 28(5):1217–20. doi: 10.1016/j.vaccine.2009.11.026 PMID: 19944790
5. Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. Journal of the American academy of dermatology. 2007; 57(6):S130–S5. doi: 10.1016/j.jaad.2007.08.046 PMID: 18021864
6. Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, HuangYL, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009; 89(6):612–6. doi: 10.2340/00015555-0725 PMID: 19997693
7. Tsai TF, Yao CA, Yu HS, Lan CC, Chao SC, Yang JH, et al. Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study. Int J Dermatol. 2015; 54(5):529–36. doi: 10.1111/ijd.12484 PMID: 25209019
8. Chao D-Y, Chien Y, Yeh Y, Hsu P, Liu I. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000–2008. Epidemiology and infection. 2012; 140(06):1131–40. doi: 10.1017/S0950268811001786 PMID: 21906410
9. Harpaz R, Ortega-Sanchez IR, Seward JF, Practices ACol. Prevention of herpes zoster. MMWR Morb Mortal Wkly Rep. 2008; 50:1–30.
10. Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke. 2009; 40(11):3443–8. doi: 10.1161/STROKEAHA.109.562017 PMID: 19815828
11. Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013; 88(6):562–70. doi: 10.1016/j.mayocp.2013.03.014 PMID: 23664666
12. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices Centers for Disease C. Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57(RR-5):1–30; quiz CE2-4. PMID: 18528318
13. Yawn BP, Wollan PC, Sauver JLS, Butterfield LC, editors. Herpes zoster eye complications: rates and trends. Mayo Clinic Proceedings; 2013: Elsevier. doi: 10.1016/j.mayocp.2013.03.014
14. Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. Journal of clinical immunology. 1987; 7(2):174–8. doi: 10.1007/BF00916011 PMID: 3033012
15. Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008; 115(2 Suppl):S3–12. doi: 10.1016/j.ophtha.2007.10.009 PMID: 18243930
16. Cohen P, Grossman M. Clinical features of human immunodeficiency virus-associated disseminated herpes zoster virus infection—a review of the literature. Clinical and experimental dermatology. 1989; 14(4):273–6. PMID: 2686873
17. Arvin AM. Varicella-zoster virus. Clinical microbiology reviews. 1996; 9(3):361–81. doi: 10.1002/0471203076.emm0234 PMID: 8809466
18. Katz J, McDermott MP, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. The Journal of Pain. 2005; 6(12):782–90. doi: 10.1016/j.jpain.2005.07.006 PMID: 16326366
19. Schmader K, George LK, Buchheit BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. Journal of Infectious Diseases. 1995; 171(3):701–4. doi: 10.1093/infdis/171.3.701 PMID: 8786622
20. Furuta Y, Ohtani F, Fukuda S, Inuyama Y, Nagashima K. Reactivation of varicella-zoster virus in delayed facial palsy after dental treatment and oro-facial surgery. Journal of medical virology. 2000; 62(1):42–5. doi: 10.1002/1096-9071(200009)62:1%3C42::AID-JMV7%3E3.0.CO;2-C PMID: 10935987
21. Whitley R, Shukla S, Crooks R. The identification of risk factors associated with persistent pain following herpes zoster. Journal of Infectious Diseases. 1998; 178(Supplement 1):S71–S5. doi: 10.1086/514274 PMID: 9852979
22. Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrani K, Gallagher WJ, Johnson R, et al. A study of shingles and the development of postherpetic neuralgia in East London. Journal of medical virology. 2003; 70(S1):S24–S30. doi: 10.1002/jmv.10316 PMID: 12627483
23. Nagasaki EM, Johnson RW, Griffin DR, Dworkin RH. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. Journal of the American Academy of Dermatology. 2002; 46(6):834–9. doi: 10.1067/mjd.2002.120924 PMID: 12063479
24. Decroix J, Partsch H, Gonzalez R, Mobacken H, Goh C, Walsh J, et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. Journal of the European Academy of Dermatology and Venereology. 2000; 14(1):23–33. doi: 10.1046/j.1468-3083.2000.00020.x PMID: 10877249
25. Kurokawa I, Kumano K, Murakawa K, Group HPPS. Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster. Journal of international medical research. 2002; 30(1):56–65. doi: 10.1177/1473230020300109 PMID: 11921500
26. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004; 62(9):1545–51. doi: 10.1212/01.WNL.0000123261.00004.29 PMID: 15136679
27. Parruti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorti A, et al. Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy. BMC medicine. 2010; 8(1):1. doi: 10.1186/1741-7015-8-58 PMID: 20937086
28. Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology. 2010; 74(10):792–7. doi: 10.1223/WNL.0b013e3181d31e5c PMID: 20200348
29. Arvin A. Aging, immunity, and the varicella—zoster virus. New England Journal of Medicine. 2005; 352(22):2266–7. doi: 10.1056/NEJMep050891 PMID: 15930416
30. Jih J-S, Chen Y-J, Lin M-W, Chen Y-C, Chen T-J, Huang Y-L, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta dermato-venereologica. 2009; 89(6):612–6. doi: 10.2340/00015555-0729 PMID: 19997693
31. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Archives of Internal Medicine. 1982; 142(2):291–3. doi: 10.1001/archinte.1982.0030150091017 PMID: 6277260
32. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004; 4(1):26–33. doi: 10.1016/S1473-3099(03)00857-0 PMID: 14720565
33. Tran TN, Ray GT, Horberg MA, Yawn BP, Castillo AL, Saddier P, et al. Complications of herpes zoster in cancer patients. Scand J Infect Dis. 2014; 46(7):528–32. doi: 10.3109/00365548.2014.901554 PMID: 24796470

34. Vandrecam T, Hintzen RQ, de Boer JH, Van der Leij A. Herpetic encephalitis is a risk factor for acute retinal necrosis. Neurology. 2008; 71(16):1268–74. Epub 2008/10/15. doi: 10.1212/01.wnl.0000327615.99124.99 PMID: 18852442

35. Atherton SS. Acute retinal necrosis: insights into pathogenesis from the mouse model. Herpes: the journal of the IHMF. 2001; 8(3):69–73. PMID: 11867023

36. Margolis T, Atherton S. Herpes simplex virus diseases: posterior segment of the eye. Ocular infection and immunity. St Louis: Mosby. 1996;1155–68.

37. Wu T-Y, Majeed A, Kuo KN. An overview of the healthcare system in Taiwan. London journal of primary care. 2010; 3(2):115–9. doi: 10.1080/17571472.2010.11493315 PMID: 25949636

38. Cheng T-M. Taiwan’s national health insurance system: high value for the dollar. Six Countries, Six Reform Models: The Healthcare Reform: Experience of Israel, The Netherlands, New Zealand, Singapore, Switzerland and Taiwan Singapore: World Scientific Publishing Co. 2010:171–204.

39. Lin H-C, Chien C-W, Ho J-D. Herpes zoster ophthalmicus and the risk of stroke A population-based follow-up study. Neurology. 2010; 74(10):792–7. doi: 10.1212/WNL.0b013e3181d31e5c PMID: 20200348

40. Chiu HF, Chen BK, Yang CY. Herpes zoster and subsequent risk of cancer: a population-based study. J Epidemiol. 2013; 23(3):205–10. doi: 10.2188/jea.JE20120155 PMID: 23545577

41. Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000–2008. Epidemiol Infect. 2012; 140 (6):1131–40. doi: 10.1017/S0950268811001786 PMID: 21906410

42. Yawn BP, Wollan PC, Kurland MJ, Sauver JLS, Saddier P, editors. Herpes zoster recurrences more frequent than previously reported. Mayo Clinic Proceedings; 2011: Elsevier. doi: 10.4065/mcp.2010.0618

43. Jeong SK, Kim IH. Recurrence rate of herpes zoster during the previous decade. Korean Journal of Dermatology. 2012; 50(4):287–9.

44. Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Archives of internal medicine. 1997; 157(11):1209–13. doi: 10.1001/archinte.1997.00440320105010 PMID: 9183232

45. Schmader K, Studenski S, MacMillan J, Grufferman S, Cohen HJ. Are stressful life events risk factors for herpes zoster? Journal of the American Geriatrics Society. 1990; 38(11):1189–94. doi: 10.1111/j.1532-5415.1990.tb01497.x PMID: 2246455

46. Thomas S, Wheeler J, Hall AJ. Case-control study of the effect of mechanical trauma on the risk of herpes zoster. BMJ. 2004; 328(7437):439. doi: 10.1136/bmj.37991.511829.F7 PMID: 14742350